We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

0 hedge funds and large institutions have $343K invested in CNS Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

42% less capital invested

Capital invested by funds: $589K → $343K (-$246K)

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$173K
2
BFA
Beacon Financial Advisory
Ohio
-$14K
3
BlackRock
BlackRock
New York
-$14K
4
Two Sigma Investments
Two Sigma Investments
New York
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$120K – – –
Bank of New York Mellon
2
Bank of New York Mellon
New York
$57K – – –
VF
3
Virtu Financial
New York
$50K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$36K – – –
FWA
5
FSM Wealth Advisors
Ohio
$10K – – –
Northern Trust
6
Northern Trust
Illinois
$9K – – –
TRCT
7
Tower Research Capital (TRC)
New York
$8K – – –
Cambridge Investment Research Advisors
8
Cambridge Investment Research Advisors
Iowa
$7K – – –
Citadel Advisors
9
Citadel Advisors
Florida
$6K – – –
State Street
10
State Street
Massachusetts
$6K – – –
Commonwealth Equity Services
11
Commonwealth Equity Services
Massachusetts
$5K – – –
UCFA
12
United Capital Financial Advisors
Texas
$5K – – –
SG
13
StoneX Group
New York
$4.46K – – –
Citigroup
14
Citigroup
New York
$4K – – –
HighTower Advisors
15
HighTower Advisors
Illinois
$4K – – –
ACI
16
Alpha Cubed Investments
California
$3K – – –
Millennium Management
17
Millennium Management
New York
$3K – – –
PCIA
18
Prime Capital Investment Advisors
Kansas
$3K – – –
Wells Fargo
19
Wells Fargo
California
$3K – – –
Renaissance Technologies
20
Renaissance Technologies
New York
– -$173K -1 Closed
BFA
21
Beacon Financial Advisory
Ohio
– -$14K – –
BlackRock
22
BlackRock
New York
– -$14K – –
Two Sigma Investments
23
Two Sigma Investments
New York
– -$9K – –

CNSP Hedge Fund Activity: Q2 2022 in Review

0 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q2 2022, worth a combined $343K — down 42% from $589K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CNSP and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $173K sold.

  • 0 institutional investors held CNS Pharmaceuticals (CNSP) as of Q2 2022, down from 1 in Q1 2022.
  • Funds reported $343K of CNS Pharmaceuticals stock for Q2 2022, down 42% quarter-over-quarter.
  • 0 funds opened new CNS Pharmaceuticals positions in Q2 2022 and 1 closed out, a net change of -1 holder.
  • The largest CNS Pharmaceuticals seller in Q2 2022 was Renaissance Technologies, an estimated $173K sold.

Based on aggregated 13F filings for Q2 2022.